Insights

Strategic partnerships Leverage Philogen's existing licensing deals and co-development history with Sun Pharma for expansion opportunities in Europe, Australia and New Zealand, focusing on Nidlegy (Daromun) and other antibody therapeutics.

Clinical-stage pipeline Target collaborations around Philogen's four anti-cancer antibody derivatives and the rheumatoid arthritis candidate, highlighting opportunities for co-development, CRO support, and later-stage licensing as registrational studies advance.

Manufacturing expansion Capitalize on the new GMP-compliant production facility in Rosia, Siena, to offer scalable manufacturing partnerships, fill-finish services, and regional supply agreements for international partners.

Angiogenesis focus Position Philogen as a specialist in angiogenesis-targeted therapies to attract pharma players seeking vascular biology expertise, with emphasis on in vivo targeting of tumor neo-vasculature and related biomarker programs.

Financial strength Highlight the company’s diversified revenue, strategic investor funding and established collaborations to pursue co-funding opportunities, milestones-based deals, and long-term strategic alliances with mid-to-large pharma.

Similar companies to Philogen S.p.A.

Philogen S.p.A. Tech Stack

Philogen S.p.A. uses 8 technology products and services including iCIMS, SAS, AutoCAD, and more. Explore Philogen S.p.A.'s tech stack below.

Media & News

Philogen S.p.A.'s Email Address Formats

Philogen S.p.A. uses at least 3 email formats:
Philogen S.p.A. Email FormatsExamplePercentage
First.Last@philogen.comJohn.Doe@philogen.com
97%
First.MiddleLast@philogen.comJohn.MichaelDoe@philogen.com
2%
First-L@philogen.comJohn-D@philogen.com
1%

Frequently Asked Questions

What is Philogen S.p.A.'s phone number?

Minus sign iconPlus sign icon
You can contact Philogen S.p.A.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Philogen S.p.A.'s stock symbol?

Minus sign iconPlus sign icon
Philogen S.p.A. is a publicly traded company; the company's stock symbol is PHIL.MI.

What is Philogen S.p.A.'s official website and social media links?

Minus sign iconPlus sign icon
Philogen S.p.A.'s official website is philogen.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Philogen S.p.A. generate?

Minus sign iconPlus sign icon
As of August 2026, Philogen S.p.A.'s annual revenue is estimated to be $1M - $10M.

What is Philogen S.p.A.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Philogen S.p.A.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Philogen S.p.A. have currently?

Minus sign iconPlus sign icon
As of August 2026, Philogen S.p.A. has approximately 185 employees across 4 continents, including Europe, Asia and North America. Key team members include Cfo: L. B., Chief Medical Officer: H. M. and Head Of Clinical Operations: B. P. Explore Philogen S.p.A.'s employee directory with LeadIQ.

What industry does Philogen S.p.A. belong to?

Minus sign iconPlus sign icon
Philogen S.p.A. operates in the Pharmaceutical Manufacturing industry.

What technology does Philogen S.p.A. use?

Minus sign iconPlus sign icon
Philogen S.p.A.'s tech stack includes iCIMS, SAS, AutoCAD, GitHub, Kubernetes, WordPress, Microsoft SQL Server and Microsoft Active Directory.

What is Philogen S.p.A.'s email format?

Minus sign iconPlus sign icon
Philogen S.p.A.'s email format typically follows the pattern of First.Last@philogen.com. Find more Philogen S.p.A. email formats with LeadIQ.

How much funding has Philogen S.p.A. raised to date?

Minus sign iconPlus sign icon
As of August 2026, Philogen S.p.A. has raised $69M in funding. The last funding round occurred on May 14, 2019 for $70M.

When was Philogen S.p.A. founded?

Minus sign iconPlus sign icon
Philogen S.p.A. was founded in 1996.
Philogen S.p.A. logo

Philogen S.p.A.

Pharmaceutical ManufacturingTuscany, Italy51-200 Employees

Philogen S.p.A. is a biopharmaceutical company focused on antibody-based therapies that target angiogenesis, the growth of new blood vessels implicated in cancer, rheumatoid arthritis, and age-related macular degeneration. Its work centers on isolating and developing lead antibody derivatives capable of selectively targeting the tumor vasculature in vivo, supported by a Zurich-based R&D unit (Philochem) and Siena-based GMP manufacturing in Siena, Tuscany. The company maintains partnerships with major pharmaceutical firms and holds an international patent portfolio, reflecting a collaborative approach and its position in the biotechnology and manufacturing landscape. Founded in 1996, Philogen operates within the pharmaceutical manufacturing and biotechnology sector from its Italian base. Recent developments include expansion of its Siena facilities and the granting of GMP certification for a new production site, with several antibody assets in clinical studies and two registrational studies planned.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
PHIL.MI
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
1996
Employees
51-200

Section iconFunding & Financials

  • $69M

    Philogen S.p.A. has raised a total of $69M of funding over 1 rounds. Their latest funding round was raised on May 14, 2019 in the amount of $70M as a Venture Round.

  • $1M - $10M

    Philogen S.p.A.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.